|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
CAMARILLA PIVOT POINT
Signal Strength: MEDIUM
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.
Ra Pharmaceuticals Inc (NASDAQ:RARX) current pivot point Camarilla is: $46.54.
The current resistance levels are: (R1) $50.458
The current support levels are: (S1) $42.702
Camarilla pivot points were discovered in 1989 by Nick Scott, a successful bond trader. The basic thesis for this strategy is a common one: That price, as most time series, has a tendency to revert to its mean.
Calculation: Camarilla Pivot Points:
1) R4 = Close + (High – Low) * 1.1/2;
2) R3 = Close + (High – Low) * 1.1/4;
3) R2 = Close + (High – Low) * 1.1/6;
4) R1 = Close + (High – Low) * 1.1/12;
5) PP = (HIGH + LOW + CLOSE) / 3;
6) S1 = Close – (High – Low) * 1.1/12;
7) S2 = Close – (High – Low) * 1.1/6;
8) S3 = Close – (High – Low) * 1.1/4;
9) S4 = Close – (High – Low) * 1.1/2;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|INO Inovio Pharma||4.36||9.3||34,675,337||-0.01||BEARISH|
|HSII Heidrick & Struggles||22.2||3.8||207,252||-0.53||BEARISH|
|FOSL Fossil Group||4.28||2.6||1,864,683||-0.05||BEARISH|
|EZPW Ezcorp Inc||4.79||2.4||1,002,907||0||BEARISH|
|CETV Central European Media||4.4||0.9||2,014,369||-0.03||BEARISH|
|ELGX Endologix Inc||1.45||0.7||546,513||-0.03||BEARISH|
|CSWI CSW Industrials||70.37||0.4||93,298||-0.74||BEARISH|